Consumer Issues Information Provision
MR's Responsibility: Collecting Data and Providing Information to Medical Institutions
The Mitsubishi Tanabe Pharma Group employs about 1,500 medical representatives (MRs) in Japan. These MRs work each day to supply medical institutions throughout the country with scientific information concerning not only the benefits of Mitsubishi Tanabe Pharma's products, but also their possible side effects, in order to ensure that the products are used appropriately. The Group's representatives are also responsible for collecting data on the efficacy and safety of the drugs at the usage stage information that could not be gleaned during R&D and providing medical professionals with data-based evaluations. Specialized MRs are responsible for products that require a high level of knowledge about specific illnesses and drug treatments. General MRs, on the other hand, cooperate with specialized MRs to provide quality information services based on the needs of medical professionals.
Providing Comprehensive Information through Seminars
Nikkei Health Seminar 21
With the cooperation of Mitsubishi Tanabe Pharma, Nikkei Health Seminar 21 was held in February 2019 under the title "I want to tell you about the intractable disease called ALS. Let's think about what we can do now to help." (Sponsored by Nihon Keizai Shimbun).
The day was divided into two parts: a lecture given by a specialist and a panel discussion to answer questions from the audience. Many people beset by ALS listened to lectures, including patients with ALS (myotropic lateral sclerosis) and their families, as well as doctors, nurses and caregivers.
Attendee interest in ALS was extremely high, and hearing about the importance of team medical care to support ALS patients, and to not just fear the disease, but to keep an eye on the progress of therapeutic research, they understood the value of getting an early start with treatments that are available now.
World Psoriasis Day 2018 Media Event -Follow Your Heart-
As a World Psoriasis Day related event on October 29, the World Psoriasis Day 2018 Media Event -Follow Your Heart- was held under the co-sponsorship of the Japan Psoriasis Association, the Japanese Society for Psoriasis Research, and nine pharmaceutical companies including Mitsubishi Tanabe Pharma in October 2018.
On that day, an event was held in two parts, with the first part being a basic explanation by a medical specialist of the disease called psoriasis, and the second part a fashion show organized by Angelica Michibata, a model who revealed last year on Instagram that she suffers from psoriasis, of clothing modeled by five patients with psoriasis that focused on clothes and fabric designed so they are easy for psoriasis patients to wear.
Media coverage was extensive, and it was a valuable seminar that fulfilled the purpose of World Psoriasis Day of raising people's awareness and giving them a correct understanding of the disease, and even those with no knowledge of the disease were welcomed.
Supporting Proper Self-Medication for Skin Problems
Mitsubishi Tanabe Pharma believes it is important to help people suffering from dermatological problems to obtain accurate information and find a treatment as quickly as possible. Toward this end, it has been conducting a variety of educational programs through TV commercials and websites.
Of these, the Hifu No Koto Site provides information to support self-medication, based on the opinions of experts, such as doctors and pharmacists.
Overseas Marketing Activities
Aiming to contribute to the health of people around the world, Mitsubishi Tanabe Pharma provides appropriate usage information through local subsidiaries overseas in order to support the appropriate use of the Company's pharmaceuticals. In addition to the U.S., these subsidiaries are located in Europe (U.K., Germany, Austria, Switzerland) and in Asia (China, South Korea, Taiwan, Indonesia, Thailand). MRs involved in drug information provision activities visit medical institutions and doctors, participate in related academic conferences, exchange opinions with specialists, and provide the latest academic information. In this way, MRs are working each day to be able to contribute to the diagnosis and treatment activities of healthcare professionals.
Radicava was approved as a treatment agent for ALS in the U.S. in May 2017 and launched in August. It is marketed by Mitsubishi Tanabe Pharma America. The Searchlight Support initiative was established to provide support to patients who have been prescribed Radicava. In line with the needs of each patient who has been prescribed Radicava, the programs provided through Searchlight Support will include treatment management, insurance reimbursement support, and 24/7 clinical nursing hotline support. In these ways, we are supporting ALS patients.
In March 2018, sales of diabetes treatment agent Canaglu began through local companies Taiwan Tanabe Seiyaku and Tai Tien Pharmaceuticals. In April 2018, product launch symposiums were held in Taiwan. In December 2018, we established a sales subsidiary in Malaysia. In these and other ways, we will continue to contribute to the health of people around the world providing a wide range of support and high-quality information, including the latest information, that meets the needs of patients.
Providing Information through Websites
Mitsubishi Tanabe Pharma has set up health support websites in Japanese for rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, ankylosing spondylitis, Behcet's disease, amyotrophic lateral sclerosis (ALS), cerebral infarction, multiple sclerosis, spinocerebellar degeneration and multiple system atrophy, liver failure, chronic kidney disease, sleep disorders, vaccines, tinea unguium, and eczema and dermatitis.
Through these websites, we are providing patients and their families with information about the symptoms, diagnoses, and treatment of these diseases in an easy-to-understand manner.
Providing Comprehensive Information through the Medical Information Center
Mitsubishi Tanabe Pharma has established its own Medical Information Center to respond directly to inquiries from patients and healthcare professionals (physicians, pharmacists, wholesalers, and others). For patients, this is the only company information center. With a motto of "reliable, accurate, and prompt," the center provides information that is easy to understand while at the same time making certain not to dispense the type of medical advice that should only come from a physician. We are working each day to improve our skills so that we identify the true needs behind the inquiries and respond in a way that increases the satisfaction of the people making inquiries.
The Medical Information Center receives more than 50,000 inquiries a year on a wide range of subjects. It also provides information on the appropriate use of the Company's products while utilizing basic pharmaceutical information and the in-house Q&A system.
Furthermore, information that the center receives about safety and quality, such as information about side effects, is shared with related departments. In this way, the center helps improve product reliability. In addition, since October 2017 we have been building a framework for effectively sharing within the Company the valuable information that is collected by the center. We are working to reflect customer feedback in the further improvement of products and in the future discovery of new products.
From April 2019, we will be in charge of maintaining pharmaceutical information at the Medical Information Center including the creation of product Q&As provided through our website. We will reflect the needs of customers more rapidly than before, which will help us to provide valuable information.
Moving forward, the center will respond flexibly to changes in the times and provide appropriate usage information for pharmaceuticals in a reliable, accurate, and prompt manner. In this way, we will work to contribute to improved health for patients.
*The number of inquiries decreased since the sales of some products were relegated to other companies in fiscal 2018.